

NCIC CLINICAL TRIALS GROUP

**INVESTIGATIONAL NEW DRUG COMMITTEE**

DISEASE SITE COMMITTEE MEETING  
FINAL OPEN AGENDA

Friday, May 1, 2009 ~ 13.30 – 16.30  
Room: Mountbatten Salon

Chair: Hal Hirte

---

1.30 p.m. Welcome from the chair

**FINAL TRIAL REPORTS**

IND.165: Rand. Phase II Docetaxel +/- OGX011 in prostate cancer	Dr. K. Chi
IND.172: Phase II Bortezomib + gemcitabine Mantle Cell Lymphoma	Dr. T. Kouroukis
IND.185: Phase II Sunitinib Ovarian Cancer	Dr. J Biagi
IND.182: Phase II Sunitinib DLBCL	Dr. R. Buckstein
IND.173: Phase I/II AZD0530 + Gemcitabine Pancreas	Dr. M Moore

2:30 p.m. **SCIENTIFIC SESSION:**  
**MOLECULAR ENDPOINTS AND OPPORTUNITIES IN EARLY CANCER CLINICAL TRIALS**  
**CHAIRS: JANET DANCEY AND HAL HIRTE**

(20') *Molecular imaging: Canada's potential to contribute to cancer drug development*  
Dr. Francois Bénard  
BC Cancer Research Centre, Vancouver BC

(20') *'Living' tumour banks and their potential for tumour-specific screening for activity*  
Dr. R. Bristow  
Princess Margaret Hospital, Toronto ON

(20') *Circulating Tumour Cells: report of NCIC CTG-OICR workshop*  
Dr. P. Bradbury  
Drug Development Fellow, NCIC CTG

3:30 p.m. Discussion

3:50 pm New / Planned Studies, Report from Closed IND meeting  
Dr. E. Eisenhauer, Dr. L. Seymour

4:30 p.m. Adjourn